Chemoinformaics analysis of (2E,4E)-Undeca-2,4-dienal
| Molecular Weight | 166.264 | nRot | 7 |
| Heavy Atom Molecular Weight | 148.12 | nRig | 3 |
| Exact Molecular Weight | 166.136 | nRing | 0 |
| Solubility: LogS | -2.78 | nHRing | 0 |
| Solubility: LogP | 3.042 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 30 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 12 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 18 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 11 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 31.1743 |
| nHD | 0 | BPOL | 18.9257 |
| QED | 0.322 |
| Synth | 2.859 |
| Natural Product Likeliness | 2.289 |
| NR-PPAR-gamma | 0.027 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.03 |
| Pgp-sub | 0.003 |
| HIA | 0.005 |
| CACO-2 | -4.581 |
| MDCK | 0.0000236 |
| BBB | 0.994 |
| PPB | 0.568046 |
| VDSS | 1.404 |
| FU | 0.226734 |
| CYP1A2-inh | 0.547 |
| CYP1A2-sub | 0.716 |
| CYP2c19-inh | 0.15 |
| CYP2c19-sub | 0.752 |
| CYP2c9-inh | 0.053 |
| CYP2c9-sub | 0.794 |
| CYP2d6-inh | 0.044 |
| CYP2d6-sub | 0.826 |
| CYP3a4-inh | 0.089 |
| CYP3a4-sub | 0.204 |
| CL | 4.907 |
| T12 | 0.639 |
| hERG | 0.044 |
| Ames | 0.867 |
| ROA | 0.893 |
| SkinSen | 0.985 |
| Carcinogencity | 0.655 |
| EI | 0.988 |
| Respiratory | 0.962 |
| NR-Aromatase | 0.522 |
| Antiviral | No |
| Prediction | 0.833432 |